
-
Syria's Kurds demand 'democratic decentralised' Syria
-
Leverkusen win to delay Bayern and Kane's title party
-
Buenos Aires farewells native pontiff with tears and calls to action
-
Turkey's opposition says Erdogan's canal plan behind latest arrests
-
Maresca hails 'nasty' Chelsea as top five bid stays alive
-
Trump raises Putin doubts after Zelensky talks at pope's funeral
-
Major blast at Iran port kills 4, injures hundreds
-
Napoleon's sword to be sold at auction in Paris
-
Iran, US discuss nuclear deal in third round of talks
-
Buenos Aires farewells native pontiff with call to action
-
Warholm sets hurdles world record at Diamond League, Holloway shocked
-
US students 'race' sperm in reproductive health stunt
-
Wikileaks founder Assange joins crowds for pope funeral
-
Leader Marc Marquez claims Spanish MotoGP sprint victory
-
Celtic win fourth successive Scottish Premiership title
-
Jackson ends drought as Chelsea boost top five push
-
Warholm sets 300m hurdles world record in Diamond League opener
-
Major blast at south Iran port kills 4, injures hundreds
-
Russia says retook Kursk from Ukraine with North Korean help
-
Francis laid to rest as 400,000 mourn pope 'with an open heart'
-
Trump, Zelensky meet on sidelines of pope's funeral
-
'Shared loss': Filipino Catholics bid Pope Francis farewell
-
Families unable to reunite as India-Pakistan border slams shut
-
Major blast at south Iran port injures hundreds
-
Foreign carmakers strive for 'China Speed' to stay in race
-
Pakistan says open to neutral probe into Kashmir attack after India threats
-
Hundreds of thousands at funeral mourn pope 'with an open heart'
-
Quartararo sets Spanish MotoGP record to claim pole
-
Hamas says open to 5-year Gaza truce, one-time hostages release
-
Iran, US hold new round of high-stakes nuclear talks
-
Up at dawn for front-row seat to history at Francis's funeral
-
Pakistan ready to 'defend sovereignty' after India threats
-
Huge crowds flock to Vatican for Pope Francis's funeral
-
Xi says China must 'overcome' AI chip challenges
-
Indian army says new exchange of gunfire with Pakistan
-
Epstein accuser Virginia Giuffre takes own life in Australia: family
-
Hundreds of buildings damaged, dozens injured in 6.3 Ecuador quake
-
India and Pakistan's Kashmir fallout hits economy too
-
Francis's funeral to be grand farewell to 'pope of the poor'
-
Pogacar faces defiant Evenepoel at Liege-Bastogne-Liege
-
Chelsea eye great escape against Barcelona in Women's Champions League
-
Iran, US to hold new round of high-level nuclear talks
-
'Energy and effort' pay off for Reds as Blues' woes continue
-
Albatross and closing birdie lift China's Liu to LPGA Chevron lead
-
On the horizon? Wave of momentum for high seas treaty
-
New to The Street Launches For The Causes(TM) Monthly Awareness Segments: Offering Free National Media to Charities and Organizations
-
Top Mistakes to Avoid When Building Credit History
-
Developing countries should fast-track US trade deals: World Bank president
-
Grizzlies' Morant 'doubtful' for must-win game 4 v Thunder
-
Trump in Rome for pope funeral in first foreign trip of new term

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
O.Johnson--AMWN